Publications by authors named "Michael Rothenberg"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

15

Total Likes

7

Extended Reach

9,864

Social Features

10
D
Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases.
Snahel Patel, Huifen Chen, Eugene Varfolomeev, Youngsu Kwon, Sreemathy Ramaswamy, Michael E Rothenberg

J Med Chem· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis.
Silvio Danese, Michael E Rothenberg, Jeremy J Lim, Han Ting Ding, Jacqueline M McBride

Clin Gastroenterol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Rona Yaeger, Meredith A McKean, Rizwan Haq, J Thaddeus Beck, Matthew H Taylor, S Michael Rothenberg

Cancer Discov· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc).
Yanke Yu, Michael E Rothenberg, Han Ting Ding, Ari Brekkan, Gizette Sperinde

J Pharmacokinet Pharmacodyn· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects.
Mariano Prado-Acosta, Seihwan Jeong, Alberto Utrero-Rico, Tatiana Goncharov, Joshua D Webster, Michael E Rothenberg

Sci Transl Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers.
Nicholas S Jones, Smita Kshirsagar, Vishnu Mohanan, Vidya Ramakrishnan, Flavia Di Nucci, Michael E Rothenberg

Clin Transl Sci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis.
Frank Wagner, John C Mansfield, Annemarie N Lekkerkerker, Yehong Wang, Mary Keir, Michael E Rothenberg

Gut· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Alexander Drilon, Manish R Sharma, Melissa L Johnson, Timothy A Yap, Shirish Gadgeel, S Michael Rothenberg

Cancer Discov· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-22 alters gut microbiota composition and function to increase aryl hydrocarbon receptor activity in mice and humans.
Jordan S Mar, Naruhisa Ota, Nick D Pokorzynski, Yutian Peng, Allan Jaochico, Michael E Rothenberg

Microbiome· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
Melissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, Justin Call, Paul R Kunk, S Michael Rothenberg

Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With Fusion-Positive Breast Cancer.
Satomi Watanabe, Masayuki Takeda, Tomoyuki Otani, Takeshi Yoshida, Kazuko Sakai, S Michael Rothenberg

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
Jonathan S Katz, Jeffrey D Rothstein, Merit E Cudkowicz, Angela Genge, Björn Oskarsson, Michael E Rothenberg

Ann Clin Transl Neurol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of Major Cardiovascular Events in Severe Asthma: U.S. Real-World and Clinical Trial-Eligible Populations.
Parul Dayal, Carlos Iribarren, Dorothy Cheung, Michael E Rothenberg, C Victor Spain

Ann Am Thorac Soc· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
Elizabeth M Kander, Manisha H Shah, Ye Zhou, Ashima Goyal, Joshua D Palmer, S Michael Rothenberg

Clin Lung Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, S Michael Rothenberg

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to RET-Specific Therapy in Fusion-Positive Anaplastic Thyroid Carcinoma.
Dora Dias-Santagata, Jochen K Lennerz, Peter M Sadow, Ryan P Frazier, Sandya Govinda Raju, S Michael Rothenberg

Thyroid· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, S Michael Rothenberg

N Engl J Med· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Selpercatinib in -Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, S Michael Rothenberg

N Engl J Med· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Benjamin J Solomon, Lavinia Tan, Jessica J Lin, Stephen Q Wong, Sebastian Hollizeck, S Michael Rothenberg

J Thorac Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring Gene Alterations.
Michael V Ortiz, Ulrike Gerdemann, Sandya Govinda Raju, Dahlia Henry, Steve Smith, S Michael Rothenberg

JCO Precis Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Fusion in Pediatric Medullary Thyroid Carcinoma.
Kirsty Hillier, Amy Hughes, Robert C Shamberger, Suzanne Shusterman, Antonio R Perez-Atayde, S Michael Rothenberg

Thyroid· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers.
Michael E Rothenberg, Michael Tagen, Jae H Chang, Janel Boyce-Rustay, Michel Friesenhahn

Clin Drug Investig· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer.
Lori J Wirth, Takashi Kohno, Hibiki Udagawa, Shingo Matsumoto, Genichiro Ishii, S Michael Rothenberg

JCO Precis Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Selective RET Inhibition With LOXO-292 in a Patient With Fusion-Positive Lung Cancer With Leptomeningeal Metastases.
Robin Guo, Mark Schreyer, Jason C Chang, S Michael Rothenberg, Dahlia Henry

JCO Precis Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis